Ying Song

US Patent:

6638709, Oct 28, 2003

Filed:

Dec 26, 2001

Appl. No.:

10/032929

Inventors:

Hsin-Chien Tai - Hackensack NJ
Alla Laufer - Brooklyn NY
Ying Song - Franklin Park NJ
Nitya G. Ray - East Hanover NJ

Assignee:

Ortec International, Inc. - New York NY

International Classification:

A01N 102

US Classification:

435 13, 623 2372

Abstract:

Processes are described for making a cryopreserved Composite Living Construct (CCLC) as well as a corresponding thawed and rinsed CCLC, comprised of separated layers of cultured fibroblasts and cultured keratinocytes, wherein the percent of cells that are viable, i. e. , the cell viability, of such CCLC is at least about 70 %. The viable cell density in the CCLC is at least about 50% of that before cryopreservation. The storage stability of the CCLC is at least about 12 months. Additionally, the metabolic activity of thawed and rinsed CCLC is at least about 50% of the Composite Living Construct (CLC) before cryopreservation. The structural integrity of CCLC is substantially the same as the CLC before cryopreservation. The process for making the CCLC comprises the steps of: providing a collagen substrate comprised of a collagen sponge layer and a nonporous to cells, semipermeable collagen layer; seeding and culturing, in the presence of a cell growth medium, fibroblasts on and within the collagen sponge layer and keratinocytes on the nonporous to cells, semipermeable collagen layer, thereby providing a CLC; equilibrating the CLC, according to a defined equilibration program with a cryoprotectant solution comprising at least chondroitin sulfate and dimethylsulfoxide; lowering the temperature, according to a programmed rate, to about -90Â C. ; and storing the CCLC at about -150Â C. or lower.

US Patent:

20040053409, Mar 18, 2004

Filed:

Aug 15, 2003

Appl. No.:

10/641655

Inventors:

Hsin-Chien Tai - Hackensack NJ, US
Alla Laufer - Brooklyn NY, US
Ying Song - Franklin Park NJ, US
Nitya Ray - East Hanover NJ, US

Assignee:

Ortec International, Inc. - New York NY

International Classification:

C12N005/08

US Classification:

435/374000, 435/397000

Abstract:

Processes are described for making a cryopreserved Composite Living Construct (CCLC) as well as a corresponding thawed and rinsed CCLC, comprised of separated layers of cultured fibroblasts and cultured keratinocytes, wherein the percent of cells that are viable, i.e., the cell viability, of such CCLC is at least about 70%. The viable cell density in the CCLC is at least about 50% of that before cryopreservation. The storage stability of the CCLC is at least about 12 months. Additionally, the metabolic activity of thawed and rinsed CCLC is at least about 50% of the Composite Living Construct (CLC) before cryopreservation. The structural integrity of CCLC is substantially the same as the CLC before cryopreservation. The process for making the CCLC comprises the steps of: providing a collagen substrate comprised of a collagen sponge layer and a nonporous to cells, semipermeable collagen layer; seeding and culturing, in the presence of a cell growth medium, fibroblasts on and within the collagen sponge layer and keratinocytes on the nonporous to cells, semipermeable collagen layer, thereby providing a CLC; equilibrating the CLC, according to a defined equilibration program with a cryoprotectant solution comprising at least chondroitin sulfate and dimethylsulfoxide; lowering the temperature, according to a programmed rate, to about -90 C.; and storing the CCLC at about -150 C. or lower. The process for preparing the CCLC to treat wounds in humans and in animals additionally comprises programmed thawing as well as a rinsing sequence to substantially remove the cryoprotectants.

US Patent:

20180044384, Feb 15, 2018

Filed:

Feb 17, 2017

Appl. No.:

15/436204

Inventors:

Xiu-Min LI - Mamaroneck NY, US
Zhenwen Zhou - Guangdong, CN
Zhigang LIU - Guangdong, CN
Ying SONG - Rego Park NY, US

International Classification:

C07K 14/28
C12N 15/70
C12R 1/63
C12N 1/20

Abstract:

The present disclosure provides compositions comprising recombinant bacterial spores. The present disclosure is also directed to vaccine based compositions, which include recombinant bacterial spores that express CTB and a peanut protein(s) on their surfaces. This disclosure also provides methods for administering these compositions as a treatment or prevention of peanut allergy.

US Patent:

20160175291, Jun 23, 2016

Filed:

Sep 17, 2015

Appl. No.:

14/857772

Inventors:

Xiu-Min Li - Mamaroneck NY, US
Nan Yang - Flushing NY, US
Chaoyi Mao - Beijing, CN
Ying Song - Elmhurst NY, US

International Classification:

A61K 31/4375
A61K 31/122
A61K 31/366

Abstract:

The present invention relates to compounds and formulations derived from traditional Chinese medicine for use for the treatment and/or mediation of food allergies, in particular peanut allergies in humans by altering the activity and/or production of IgE.

US Patent:

20050100876, May 12, 2005

Filed:

Aug 25, 2003

Appl. No.:

10/646802

Inventors:

Bijan Khirabadi - Rockville MD, US
Ying Song - Mt. Pleasant SC, US
Kelvin Brockbank - Charleston SC, US

Assignee:

ORGAN RECOVERY SYSTEMS, INC. - Des Plaines IL

International Classification:

A01N001/02

US Classification:

435001100

Abstract:

A method for vitrification of a tissue or organ includes immersing the tissue or organ in increasing concentrations of cryoprotectant solution at a temperature greater than −15 C. to a cryoprotectant concentration sufficient for vitrification; cooling the tissue or organ at an average rate of from 2.5-100 C. per minute to a temperature between −80 C. and the glass transition temperature; and further cooling the tissue or organ at an average rate less than 30 C. per minute to a temperature below the glass transition temperature to vitrify the tissue or organ. After the vitrified tissue or organ has been stored, the tissue or organ may be removed from vitrification by warming the tissue or organ at an average rate of from 20-40 C. per minute to a temperature between −80 C. and the glass transition temperature; further warming the tissue or organ at a rate greater than 80 C. per minute to a temperature above −75 C.; and reducing the concentration of the cryoprotectant. Tissues or organs treated in this manner exhibit near normal functions, for example, blood vessels exhibit near normal smooth muscle contractility and normal graft functions.